Research.Patient.info
Metastatic Urothelial Carcinoma research hub
2 indexed studies · 0 currently recruiting
- active not recruitingPHASE1, PHASE2
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
This study is looking at a new combination of treatments for advanced bladder cancer. Doctors want to see how safe and effective a new drug, sacituzumab tirumotecan, is when given with enfortumab vedotin. It's a key step in finding better ways to treat this type of cancer.
United States · Canada · France - active not recruitingPHASE1, PHASE2
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
This study is looking into a new treatment for advanced bladder cancer. It combines two drugs, tazemetostat and pembrolizumab, to see if they work better together. Doctors want to find the safest dose and understand how well this combination fights the cancer.
United States · Canada